2015
DOI: 10.1002/jcp.25014
|View full text |Cite
|
Sign up to set email alerts
|

GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases

Abstract: Prior tumor cell studies have shown that the drugs sorafenib (Nexavar) and regorafenib (Stivarga) reduce expression of the chaperone GRP78. Sorafenib/regorafenib and the multi-kinase inhibitor pazopanib (Votrient) interacted with sildenafil (Viagra) to further rapidly reduce GRP78 levels in eukaryotes and as single agents to reduce Dna K levels in prokaryotes. Similar data were obtained in tumor cells in vitro and in drug-treated mice for: HSP70, mitochondrial HSP70, HSP60, HSP56, HSP40, HSP10, and cyclophilin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
59
0
1

Year Published

2016
2016
2018
2018

Publication Types

Select...
5
2

Relationship

3
4

Authors

Journals

citations
Cited by 56 publications
(64 citation statements)
references
References 117 publications
(125 reference statements)
3
59
0
1
Order By: Relevance
“…The role of HSP27 in the regulation of other PI3K pathway regulated processes also connects our prior studies with [sorafenib/regorafenib + sildenafil] to the new data in this manuscript [6, 8]. As GRP78 and HSP27 both act to maintain PI3K/AKT signaling they also could be thought to very likely play a key role in the regulation of the PI3K-regulated kinase mTOR.…”
Section: Discussionsupporting
confidence: 78%
See 2 more Smart Citations
“…The role of HSP27 in the regulation of other PI3K pathway regulated processes also connects our prior studies with [sorafenib/regorafenib + sildenafil] to the new data in this manuscript [6, 8]. As GRP78 and HSP27 both act to maintain PI3K/AKT signaling they also could be thought to very likely play a key role in the regulation of the PI3K-regulated kinase mTOR.…”
Section: Discussionsupporting
confidence: 78%
“…From our prior studies in Tavallai et al and Roberts et al we also were aware that tumors treated with [sorafenib/regorafenib + sildenafil] re-grow after therapy with higher ERBB1 phosphorylation and that the combination of [sorafenib/regorafenib + sildenafil] can reduce the detection by in-cell western/immuno-fluorescence of the chaperones HSP90, GRP78 and HSP70 [6, 8]. The “big-picture” conclusions we had previously made concerning the biology of the [sorafenib/regorafenib + sildenafil] drug combination prior to the present manuscript were that the combination kills tumor cells selectively over non-transformed cells and does so by primarily inactivating and down-regulating anti-apoptotic protein expression together with those of chaperones which causes both death receptor activation and mitochondrial dysfunction as well as a prolonged intense endoplasmic reticulum stress response leading to high levels of autophagy flux and an apparent necroptotic form of tumor cell death.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The enhanced killing effect of the drug combination was associated with enhanced PERK-dependent ER stress signaling and autophagosome formation, as well as through death receptor activation [6]. Congruent data were obtained using the parent drug of OSU-03012, celecoxib, and also with the multi-kinase inhibitors sorafenib, regorafenib and pazopanib [7,8]. These pre-clinical studies have resulted in two open clinical trials; in all solid tumor patients (NCT02466802) where patients are receiving increasing once daily dosing with regorafenib and sildenafil; in recurrent glioblastoma patients (NCT01817751) where they receive sorafenib, sildenafil and valproate twice daily.…”
Section: Commentarymentioning
confidence: 99%
“…From this realization we have performed studies to determine whether OSU-03012 could alter virus reproduction. OSU-03012 and the multi-kinase inhibitors sorafenib (Nexavar) and pazopanib (Votrient) reduced the expression of multiple chaperones in the HSP70 family and the HSP90 family; effects that were magnified by the PDE5 inhibitor sildenafil [7,22,23]. And, because our drug combinations were inhibiting the chaperone function of many diverse chaperones, we found that OSU-03012 or sorafenib or pazopanib could strongly inhibit the reproduction of antiviral a wide range of DNA and RNA viruses.…”
Section: Commentarymentioning
confidence: 99%